Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
limosilactobacillus reuteri 3613
- Development stage
- Unknown
- Lead developer
- ARM & HAMMER Performance Products
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Limosilactobacillus reuteri 3613 is a specific probiotic strain developed by PrecisionBiotics Group (a subsidiary of Novonesis) for the prevention and management of recurrent urinary tract infections (UTIs) in women. As a live biotherapeutic product (LBP), it is designed to be administered orally to modulate the urogenital microbiome, creating an environment that is inhospitable to uropathogens such as Escherichia coli. The strain works through mechanisms of competitive exclusion, where it outcompetes pathogenic bacteria for adhesion sites and nutrients, and by producing antimicrobial metabolites that inhibit pathogen growth. It is currently being evaluated in clinical trials to determine its efficacy in reducing the frequency of symptomatic UTI episodes in women with a history of recurrence.
- Other names
- L. reuteri 3613Limosilactobacillus reuteri strain 3613
Beyond the preview
Go deeper on limosilactobacillus reuteri 3613.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on limosilactobacillus reuteri 3613.